Listen to article
6:25Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 5 October 2026
Read article
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
Let’s be honest, investing in biotech has always felt a bit like playing the lottery. You’re betting on a single, brilliant idea, a ‘magic bullet’ that might cure a terrible disease and make you a fortune. The problem, of course, is that most of these bullets miss. Cancer, in particular, is a wily and adaptable foe. It learns, it mutates, and it finds a way around our cleverest single-pronged attacks. It’s a frustrating and often heartbreaking reality, for patients and investors alike.
But what if we’ve been thinking about it all wrong? What if the answer isn’t one magic bullet, but two working in perfect, brutal harmony? That, to me, is the real story behind the recent buzz around a bladder cancer trial from Astellas and Pfizer. It’s a sign that the game is changing.
The science, when you strip it back, is beautifully simple. The trial combined two different types of drugs. One is what’s called an antibody-drug conjugate, which is a bit like a microscopic guided missile that delivers a toxic payload directly to cancer cells. The other is an immunotherapy, a drug that essentially takes the brakes off the body’s own immune system, letting it finally see and attack the tumour.
Think of it as a pincer movement. While one drug is attacking the enemy head-on, the other is unleashing your own internal cavalry to attack from the flank. Even if some cancer cells develop a defence against the guided missile, they’re left exposed to the immune system. It’s a far more robust strategy, and it’s showing results that are making everyone in the industry sit up and take notice. This isn’t just another drug, it’s a whole new philosophy for fighting the disease.
So, what does this mean for someone looking to invest? Well, it suggests the old model of betting on a single company with a single wonder drug might be outdated. The future could lie with the companies developing the components for these new therapeutic cocktails. It’s a more complex landscape, certainly, but potentially a more rewarding one.
You have companies focusing on highly targeted therapies, others using artificial intelligence to figure out which patients will respond best, and some building a whole portfolio of different approaches. The key is that they are all creating the building blocks for tomorrow’s combination treatments. For those looking to understand this evolving sector, exploring a curated portfolio like the Oncology Stocks: Could Combination Therapies Drive Growth? basket could be a sensible starting point. It’s a way to gain exposure to the theme rather than trying to pick a single, elusive winner from a field of hundreds.
Of course, let’s not get carried away. This is still oncology. The path from a promising trial to a blockbuster drug is littered with expensive failures. Clinical trials can and do go wrong for a thousand different reasons. Regulators can be unpredictable, and the competition is absolutely ferocious. Combining therapies also adds new layers of complexity. How do the drugs interact? What’s the right dosage? It’s a minefield of clinical and financial risk. Anyone who tells you this is a sure thing is either a fool or a liar. But the potential for more durable and effective treatments could, just maybe, start to tilt the odds a little more in our favour.
View the full Basket:Oncology Stocks: Could Combination Therapies Drive Growth?
All investments carry risk and you may lose money.
View the full Basket:Oncology Stocks: Could Combination Therapies Drive Growth?
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 5 October 2026
Read article
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
